DARZALEX®: New identified risk of Hepatitis B reactivation and recommendations for HBV screening

A Dear Healthcare Professional Letter has been issued by Johnson & Johnson Pte Ltd to inform all healthcare professionals of the newly identified risk of Hepatitis B reactivation associated with the use of DARZALEX® (daratumumab) and recommendations for HBV screening in patients treated with this product. The Singapore package insert has been updated to reflect the new safety information. Please refer to the letter for details.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.